• 혜화의학회지
• /
• 제17권2호
• /
• pp.137-148
• /
• 2008

In order to investigate the effects of JHG on immune cells in BALF, clinically prescribed JHG was tested using OVA induced asthma animal model. The results are shown below: 1. JHG significantly reduced the total number of cells in BALF compared to that of the control at 400 mg/kg doses. 2. JHG significantly reduced the number of CD3+/CD69+ cells in BALF at 400 and 200 mg/kg doses. 3. JHG significantly reduced the number of CCR3+ cells in BALF at 400 and 200 mg/kg doses. 4. JHG significantly reduced the number of B220+/CD22+ cells in BALF at 400 and 200 mg/kg doses. 5. JHG significantly reduced the number of B220+/IgE+ cells in BALF at 400 and 200 mg/kg doses. 6. JHG significantly reduced the number of B220+/CD45+ cells in BALF at 400 and 200 mg/kg doses. From the results above, anti-asthmatic efficacy of JHG through anti-oxidative activity as well as immune control activity has been experimentally proven. In depth study of JHG on various pathological factors and individual drug contents of JHG should follow.